TY - JOUR
T1 - British Gynaecological Cancer Society recommendations and guidance on patient-initiated follow-up (PIFU)
AU - Newton, Claire
AU - Nordin, Andy
AU - Rolland, Philip
AU - Ind, Thomas
AU - Larsen-Disney, Peter
AU - Martin-Hirsch, Pierre
AU - Beaver, Kinter
AU - Bolton, Helen
AU - Peevor, Richard
AU - Fernandes, Andrea
AU - Kew, Fiona
AU - Sengupta, Partha
AU - Miles, Tracie
AU - Buckley, Lynn
AU - Manderville, Helen
AU - Gajjar, Ketan
AU - Morrison, Jo
AU - Ledermann, Jonathan
AU - Frost, Jonathan
AU - Lawrence, Alexandra
AU - Sundar, Sudha
AU - Fotopoulou, Christina
PY - 2020/5/4
Y1 - 2020/5/4
N2 - The National Cancer Survivorship Initiative through the National Health Service (NHS) improvement in the UK started the implementation of stratified pathways of patient-initiated follow-up (PIFU) across various tumor types. Now the initiative is continued through the Living With and Beyond Cancer program by NHS England. Evidence from non-randomized studies and systematic reviews does not demonstrate a survival advantage to the long-established practice of hospital-based follow-up regimens, traditionally over 5 years. Evidence shows that patient needs are inadequately met under the traditional follow-up programs and there is therefore an urgent need to adapt pathways to the needs of patients. The assumption that hospital-based follow-up is able to detect cancer recurrences early and hence improve patient prognosis has not been validated. A recent survey demonstrates that follow-up practice across the UK varies widely, with telephone follow-up clinics, nurse-led clinics and PIFU becoming increasingly common. There are currently no completed randomized controlled trials in PIFU in gynecological malignancies, although there is a drive towards implementing PIFU. PIFU aims to individualize patient care, based on risk of recurrence and holistic needs, and optimizing resources. The British Gynaecological Cancer Society wishes to provide the gynecological oncology community with guidance and a recommendations statement regarding the value, indications, and limitations of PIFU in endometrial, cervical, ovarian, and vulvar cancers in an effort to standardize practice and improve patient care.
AB - The National Cancer Survivorship Initiative through the National Health Service (NHS) improvement in the UK started the implementation of stratified pathways of patient-initiated follow-up (PIFU) across various tumor types. Now the initiative is continued through the Living With and Beyond Cancer program by NHS England. Evidence from non-randomized studies and systematic reviews does not demonstrate a survival advantage to the long-established practice of hospital-based follow-up regimens, traditionally over 5 years. Evidence shows that patient needs are inadequately met under the traditional follow-up programs and there is therefore an urgent need to adapt pathways to the needs of patients. The assumption that hospital-based follow-up is able to detect cancer recurrences early and hence improve patient prognosis has not been validated. A recent survey demonstrates that follow-up practice across the UK varies widely, with telephone follow-up clinics, nurse-led clinics and PIFU becoming increasingly common. There are currently no completed randomized controlled trials in PIFU in gynecological malignancies, although there is a drive towards implementing PIFU. PIFU aims to individualize patient care, based on risk of recurrence and holistic needs, and optimizing resources. The British Gynaecological Cancer Society wishes to provide the gynecological oncology community with guidance and a recommendations statement regarding the value, indications, and limitations of PIFU in endometrial, cervical, ovarian, and vulvar cancers in an effort to standardize practice and improve patient care.
KW - follow-up (FU)
KW - gynaecological malignancies
KW - gynaecology oncology
KW - patient initiated follow-up (PIFU)
UR - http://www.scopus.com/inward/record.url?scp=85083712879&partnerID=8YFLogxK
U2 - 10.1136/ijgc-2019-001176
DO - 10.1136/ijgc-2019-001176
M3 - Review article
C2 - 32312719
AN - SCOPUS:85083712879
SN - 1048-891X
VL - 30
SP - 695
EP - 700
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
IS - 5
ER -